What is the translation of " GENERALLY CONSISTENT " in Slovenian?

• na splošno skladen
• na splošno ujemali
• na splošno v skladu
• na splošno skladni

Examples of using Generally consistent in English and their translations into Slovenian

Secondary efficacy outcomes were generally consistent with the primary outcome.
Sekundarni rezultati učinkovitosti so bili večinoma v skladu s primarnimi.

Efficacy across subgroups, including age, gender, body mass index(BMI), renal function, extent of index PE, location of DVT thrombus, and prior parenteral heparin use was generally consistent.
Učinkovitost v podskupinah glede na starost, spol, indeks telesne mase(ITM), delovanje ledvic, stopnjo indeksa PE, mesto trombusa pri GVT in predhodno uporabo parenteralnega heparina je bila na splošno konsistentna.

This Indian language is generally consistent in both spelling and pronunciation, so it is not too difficult to master.
Ta indijski jezik je na splošno dosleden v zapisu in izgovorjavi, zato se ga ni težko naučiti.

The adverse reaction profile of tigecycline in these 25 subjects was generally consistent with that in adults.
Profil neželenih učinkov tigeciklina pri teh 25 preiskovancih je bil na splošno skladen s profilom pri odraslih.

Adverse reactions were generally consistent with those seen in previous studies of the individual components.
Neželeni učinki so bili načeloma konsistentni s tistimi iz predhodnih študij posameznih zdravilnih učinkovin.

The analogous median apparent volume of distribution at steady-state(Vz/Fss) was also generally consistent and ranged from 43.2 L to 121 L.
Analogni mediani navidezni porazdelitveni volumen v stanju ravnovesja(Vz/Fss) je bil tudi na splošno skladen in je segal od 43,2 l do 121 l.

The budgetary plans of these countries are generally consistent with the goal of correcting the excessive deficits within the time limits specified by the Council.
Proračunski načrti teh držav so na splošno v skladu s ciljem odprave čezmernih primanjkljajev v rokih, ki jih je določil Svet.

The safety profile of panitumumab in patients whose tumour express KRAS wild-type(n= 123) was generally consistent with overall mCRC monotherapy set described above.
Varnostne značilnosti panitumumaba pri bolnikih z eksprimiranim divjim tipom KRAS(n= 123) so se na splošno ujemale z zgoraj opisanim celotnim naborom monoterapije za mKRR.

The overall safety results from this study were generally consistent with the known safety profile of tadalafil and with adverse events(AEs) expected in a paediatric DMD population receiving corticosteroids.
Skupni rezltati o varnosti so bili v tej študiji na splošno skladni z znanim varnostnim profilom tadalafila in z neželenimi učinki, pričakovanimi v pediatrični populaciji z DMD, ki prejema kortikosteroide.

Post-marketing reports of post-injection syndrome since the marketing authorization of ZYPADHERA are generally consistent with the experience seen in clinical studies.
Po pridobitvi dovoljenja za promet z zdravilom ZYPADHERA so poročila v obdobju trženja o sindromu po injiciranju v splošnem skladna z izkušnjami iz kliničnih študij.

The overall safety results from this study were generally consistent with the known safety profile of tadalafil and with adverse events(AEs) expected in a paediatric DMD population receiving corticosteroids.
Rezultati splošne varnosti iz te študije so bili na večinoma skladni z znanim varnostnim profilom tadalafila in z neželenimi dogodki(AE), ki so pričakovani pri pediatrični populaciji z DMD, ki prejema kortikosteroide.

In patients, the median apparent volume of distribution(Vz/F) of the first dose ranged from 50.5 L to 92 L and was generally consistent across the dose groups from 3.2 mg to 32 mg.
Pri bolnikih je mediani navidezni porazdelitveni volumen(Vz/F) prvega odmerka segal od 50,5 l do 92 l in je bil na splošno skladen v skupinah odmerkov od 3,2 mg do 32 mg.

In relation to the broader set of EU policies, the INSPIRE Directive is generally consistent with the objectives of the European Interoperability Framework and the broader objectives of the EU Digital Single Market.
Kar zadeva širši niz politik EU, je direktiva INSPIRE na splošno skladna s cilji evropskega okvira interoperabilnosti in širšimi cilji enotnega digitalnega trga EU.

With regards to the safety profile, the most common adverse events observed during treatment with Plegridy are considered to be manageable and generally consistent with those seen with non-pegylated interferon products.
Glede na varnostni profil so bili najpogostejši neželeni učinki, opaženi med zdravljenjem z zdravilom Plegridy, obvladljivi in na splošno skladni z neželenimi učinki, ki so jih opazili pri nepegiliranih interferonih.

Regardless of the subgroup evaluated, PFS was generally consistent with that observed in the ITT population for both treatment groups.
Ne glede na ocenjene podskupine je bila PFS na splošno v skladu z opazovano v populaciji ITT za obe skupini zdravljenja.

Treatment effects in evaluable subgroups(e.g., age, gender, race, baseline HbA1c, baseline visual acuity, prior anti-VEGF therapy) in each study and in the combined analysis were generally consistent with the results in the overall populations.
Učinkovitost zdravljenja v vseh ocenjenih podskupinah(npr. glede na starost, spol, raso, izhodiščni HbA1c, ostrino vida ob izhodišču, predhodno zdravljenje z zaviralci VEGF) v vsaki študiji in v analizi združenih podatkov je bila običajno v skladu z izsledki za celotno populacijo.

The safety profile of Somatropin Biopartners is generally consistent with the well known safety profile of daily growth hormone treatments.
Varnostni profil zdravila Somatropin Biopartners je v glavnem v skladu z dobro znanim varnostnim profilom vsakodnevnega zdravljenja z rastnim hormonom.

Safety data profiles from individual pivotal studies(including studies in moderately renally impaired patients; older patients[≥ 55 years of age to≤ 80 years of age]; patients with increased CV-risk) were generally consistent with the adverse reactions identified in this table.
Profili varnostnih podatkov iz posameznih ključnih študij(vključno s študijami z bolniki z zmerno okvaro ledvic, s starejšimi bolniki[starih od ≥ 50 do ≤ 80 let]; bolnikih s povečanim tveganjem za kardiovaskularne bolezni) so se večinoma ujemali z neželenimi učinki, ki so navedeni v tej preglednici.

The permissive uses explicitly authorized by the proposed regulations are generally consistent with the safe harbor principles or are otherwise allowed by another exception.
Dovoljene oblike uporabe, ki jih predlagani predpisi posebej odobrijo, so na splošno v skladu z načeli varnega pristana ali jih dovoljuje kaka druga izjema.

Results were generally consistent in subgroups according to aetiology(primary and connective tissue disease-associated PAH), WHO functional class, gender, race, location, mean PAP and PVRI.
Rezultati so bili po podskupinah praviloma skladni glede na etiologijo(primarna PAH in PAH, povezana z boleznimi vezivnega tkiva), funkcijski razred po SZO, spol, raso, lokacijo, povprečni pljučni arterijski tlak in indeks pljučne žilne upornosti.

The adverse reactions profile seen in this paediatric study was generally consistent with that in adults(see table above).
Profil neželenih učinkov, ki so ga opažali v tej pediatrični študiji, je bil na splošno skladen s tistim, ki so ga opažali pri odraslih(glejte preglednico zgoraj).

Results were generally consistent in subgroups according to baseline walking distance, aetiology(primary and CTD-associated PAH), WHO functional class, gender, race, location, mean PAP and PVRI.
Rezultati so bili praviloma konsistentni po podskupinah glede na prehojeno razdaljo v začetku študije, etiologijo(primarna PAH in PAH, povezana z boleznimi vezivnega tkiva), funkcijski razred po SZO, spol, raso, lokacijo, povprečni pljučni arterijski tlak in indeks pljučne žilne upornosti.

Safety findings in the single-arm Phase 2 AURAex and AURA2 studies were generally consistent with those observed in the AURA3 TAGRISSO arm.
Izsledki o varnosti v študijah 2. faze z eno samo skupino AURAex in AURA2 so se na splošno ujemali s tistimi, ki so jih ugotovili v skupini z zdravilom TAGRISSO v študiji AURA3.

Changes in exposures of the metabolite were generally consistent with that observed with dasabuvir except for studies with CYP2C8 inhibitor, gemfibrozil, where the metabolite exposures decreased by up to 95% and CYP3A inducer, carbamazepine, where the metabolite exposures decreased by only up to 39%.
Spremembe v izpostavljenosti presnovku so se na splošno skladale s tistimi, ki so bile opažene z dasabuvirjem, razen v študijah z zaviralcem CYP2C8 gemfibrozilom, v katerih se je izpostavljenost presnovku zmanjšala do 95%, in v študijah induktorja CYP3A karbamazepina, v katerih se je izpostavljenost presnovku zmanjšala le do 39%.

The safety findings observed with long-term ambrisentan exposure in this study were generally consistent with those observed in the 12 week placebo-controlled studies.
Izsledki o varnosti, zabeleženi med dolgotrajno izpostavljenostjo ambrisentanu v tej študiji, so se na splošno ujemali s tistimi v 12- tedenskih študijah, kontroliranih s placebom.

The safety of Perjeta in Phase I and II studies was generally consistent with that observed in the CLEOPATRA, NEOSPHERE and TRYPHAENA trials, although the incidence and most common adverse drug reactions(ADRs) varied depending on whether Perjeta was administered as monotherapy or with concomitant anti-neoplastic agents.
Varnost zdravila Perjeta v preskušanjih faze I in II je bila na splošno skladna z opažanji v preskušanjih CLEOPATRA, NEOSPHERE in TRYPHAENA, čeprav so se incidenca in najpogostejši neželeni učinki razlikovali glede na to, ali je bilo zdravilo Perjeta uporabljeno v monoterapiji ali sočasno z drugimi antineoplastičnimi zdravili.

The adverse reactions observed for the combination of dolutegravir+ abacavir/lamivudine in an analysis of pooled data from Phase IIb to Phase IIIb clinical trials were generally consistent with the adverse reaction profiles for the individual components dolutegravir, abacavir and lamivudine.
Neželeni učinki, zabeleženi pri kombinaciji dolutegravirja+ abakavirja/lamivudina v analizi zbranih podatkov iz kliničnih preskušanj faze IIb do IIIb, so bili na splošno skladni s profili neželenih učinkov posameznih komponent: dolutegravirja, abakavirja in lamivudina.

The adverse reaction profile of tigecycline in these 58 subjects was generally consistent with that in adults, with the exception of nausea(48.3%), vomiting(46.6%) and elevated lipase in serum(6.9%) which were seen at greater frequencies in children than in adults.
Profil neželenih učinkov tigeciklina pri teh 58 preiskovancih je bil na splošno skladen s profilom pri odraslih, razen pri navzei(48,3%), bruhanju(46,6%) in zvišanju ravni lipaze v serumu(6,9%), saj so se ti neželeni učinki pri otrocih pojavljali pogosteje kot pri odraslih.

The efficacy results for pre-specified major subgroups(with dose reduction as required), including age, body weight, gender, status of renal function, prior stroke or TIA, diabetes and P-gp inhibitors were generally consistent with the primary efficacy results for the overall population studied in the trial.
Rezultati učinkovitosti za vnaprej določene pomembne podskupine(po potrebi z zmanjšanjem odmerka), vključno s starostjo, telesno maso, spolom, stanjem funkcije ledvic, predhodno možgansko kapjo ali TIA, s sladkorno boleznijo in z inhibitorji P-gp, so se na splošno ujemali z rezultati primarne učinkovitosti za celotno populacijo, ki so jo proučevali v študiji.

In both studies, frequency, type and severity of adverse reactions observed in children and adolescents have been generally consistent with those observed in adults, with the exception of infections which were reported at a higher frequency, especially in children below the age of 3 years.
V obeh študijah so se pogostnost pojavljanja, vrsta in stopnja izraženosti neželenih učinkov, ki so jih opažali pri otrocih in mladostnikih, večinoma ujemale s tistimi, ki so jih opažali pri odraslih, z izjemo okužb, o katerih so poročali pogosteje, zlasti pri otrocih, mlajših od 3 let.